ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: 387 • 2015 ACR/ARHP Annual Meeting

    Features of 847 Childhood-Onset Systemic Lupus Erythematousus Patients in Three Age-Related Groups at Diagnosis: A Brazilian Multicenter Study

    Clovis A Silva1, Roberta C. Gomes Sr.2, Marco F. Silva3, Katia T. Kozu4, Eloisa Bonfá5, Rosa M R Pereira6, Maria Teresa Terreri7, Claudia S. Magalhães Sr.8, Silvana B. Sacchetti Sr.9, Roberto Marini Sr.10, Melissa Fraga11, Luciana M. Carvalho Sr.12, Cássia M. Barbosa13 and Magda Carneiro-Sampaio Sr.14, 1Pediatric Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Pediatric Rheumatology Unit-Children’s Institute,, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 4Pediatrics, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 5Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 7Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, 8Pediatric Rheumatology Unit, São Paulo State University – Faculdade de Medicina de Botucatu, São Paulo, Brazil, 9Pediatric Rheumatology Unit, Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, 10Pediatric Rheumatology Unit, State University of Campinas, São Paulo, Brazil, 11Pediatrics, Universidade Federal de São Paulo / UNIFESP, São Paulo, Brazil, 12Pediatric Rheumatology Unit, Ribeirão Preto Medical School – University of São Paulo, São Paulo, Brazil, 13Pediatric Rheumatology Unit, Hospital Infantil Darcy Vargas, São Paulo, Brazil, 14Pediatric Allergology and Immunology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Previous retrospective evaluations suggested that age at diagnosis may influence disease expression in terms of initial clinical presentation, pattern of organ involvement and serological…
  • Abstract Number: 826 • 2015 ACR/ARHP Annual Meeting

    Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.

    Len Harty1, Deirdre Fitzgerald2, Michael Henry2, John Ryan3 and Sinead Harney3, 1Cork University Hospital, Cork, Ireland, 2Respiratory, Cork University Hospital, Cork, Ireland, 3Rheumatology, Cork University Hospital, Cork, Ireland

    Background/Purpose: Despite the advent of potent immunosuppressive and vasoactive therapies it is not clear that longevity of patients with systemic sclerosis (SSc) has improved. Therefore…
  • Abstract Number: 1033 • 2015 ACR/ARHP Annual Meeting

    Novel Ligand-Independent Peptide Inhibitors of Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) and T Cell Receptor (TCR): Efficacy in a Collagen-Induced Arthritis Model Suggests New Targeted Treatment for Rheumatoid Arthritis

    Zu T. Shen and Alexander B. Sigalov, SignaBlok, Inc., Shrewsbury, MA

    Background/Purpose: Macrophages and T cells are central to the pathophysiology of autoimmune diseases. Synovial macrophages, synovial fibroblasts and infiltrating T lymphocytes are the most abundant…
  • Abstract Number: 2201 • 2014 ACR/ARHP Annual Meeting

    Haematological Complications in Rheumatic Diseases: Not Only Lymphomas

    Elena Elefante1, Chiara Baldini1, Alice Parma1, Elisa Cioffi2, Francesco Ferro1, Roberta Vagelli2, Martina Rousseau3, Rosaria Talarico2, Sara Galimberti3 and Stefano Bombardieri2, 1University of Pisa, Rheumatology Unit, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3Hematology Unit, Pisa, Italy

    Background/Purpose Several immunological abnormalities have been reported among patients affected by myelodisplastic syndrome (MDS). On the other hand, a relatively limited number of studies have…
  • Abstract Number: 2190 • 2014 ACR/ARHP Annual Meeting

    Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort

    Adela Gallego Flores1, Carmen Carrasco Cubero2, Raul Veroz Gonzalez1, Luz Maria Mellado Narciso1, Tamara Libertad Rodriguez Araya1, Juan Jose Aznar Sánchez1 and Eugenio Chamizo Carmona1, 1Rheumatology, Hospital de Mérida, Mérida, Spain, 2Rheumatology, Hospital de Merida, Mérida, Spain

    Background/Purpose Diffuse interstitial lung disease (ILD) can be associated with connective tissue diseases (CTD), and can increase morbidity and mortality significantly. The predominant patterns of…
  • Abstract Number: 2182 • 2014 ACR/ARHP Annual Meeting

    Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases

    Alexandra Antonioli1, Brandon Renner2, Joshua Thurman3, V. Michael Holers4 and Jonathan Hannan4, 1Department of Rheumatology, University of Colorado School of Medicine, Aurora, CO, 2University of Colorado School of Medicine, Aurora, CO, 3Renal Division, University of Colorado School of Medicine, Aurora, CO, 4Rheumatology Division, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose Complement plays a central role in the pathogenesis of systemic lupus erythematosus (SLE) wherein inappropriate activation of complement leads to substantial tissue damage, especially…
  • Abstract Number: 2167 • 2014 ACR/ARHP Annual Meeting

    Snapin Is Critical for Cathepsin D Activation and the Normal Lysosomal Function

    Bo Shi1, Qi Quan Huang2, Robert Birkett2, Renee E. Koessler1, Andrea Dorfleutner1, Christian Stehlik1 and Richard M. Pope1, 1Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, 2Medicine/Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL

    Background/Purpose:  Our recent data indicates that Snapin, a SNAP associated protein, is critical for maintaining healthy autophagy and monocytes to macrophage (MFs) differentiation which requires…
  • Abstract Number: 1359 • 2014 ACR/ARHP Annual Meeting

    Care of Women with Rheumatological Conditions during Family Planning and Pregnancy

    Megan E. B. Clowse1, Munther Khamashta2, Daphnee S. Pushparajah3 and Eliza Chakravarty4, 1Rheumatology, Duke University Medical Center, Durham, NC, 2Graham Hughes Lupus Research Laboratory, The Rayne Institute, London, United Kingdom, 3UCB Pharma, Brussels, Belgium, 4OMRF, Oklahoma City, OK

     Background/Purpose Rheumatological diseases often affect women of reproductive age and can impact pregnancy outcomes. There is a need to understand how patients (pts) are managed…
  • Abstract Number: 1073 • 2014 ACR/ARHP Annual Meeting

    Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus

    Rishi Desai1, Krista Huybrechts2, Brian Bateman2, Helen Mogun2, Sonia Hernandez-diaz3 and Seoyoung C. Kim4, 1PharmacoEpidemiology & PharmacoEconomics, Brigham and Women's Hospital, Boston, MA, 2Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 3Harvard School of Public Health, Boston, MA, 4Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose:   Little is known about the trends of medication use in pregnant women with autoimmune disorders. The objective of the current study was to…
  • Abstract Number: 845 • 2014 ACR/ARHP Annual Meeting

    The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication

    Layla Saliba1, Guillaume Moulis2, Malak Aboutaam3, Grégory Pugnet2, Vanessa Rousseau1, Leila Chebane1, Nadine Petitpain4, Bernadette Baldin5, Jean-Louis Montastruc1 and Haleh Bagheri1, 1Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, 2Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, 3Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, 4Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, 5Nice University Hospital, Pharmacovigilance Regional Center, Nice, France

    Background/Purpose: The risk of cancer with TNF-a inhibitor (TNFi) in patients concomitantly exposed to non-biological immunosuppressants (NBIS) is highly debated in RA, AS and psoriasis/PsA.…
  • Abstract Number: 525 • 2014 ACR/ARHP Annual Meeting

    The Genetic Basis of Sjögren’s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort

    Lindsey A. Criswell1, Kimberly E. Taylor2,3, Quenna Wong4, David M. Levine4, Caitlin McHugh4, Cathy Laurie4, Kimberly Doheny5, Mi Y. Lam6, Alan N. Baer7, Stephen Challacombe8, Yi Dong9, Hector Lanfranchi10, Morten Schiødt11, M. Srinivasan12, Susumu Sugai13, Hisanori Umehara14, Frederick B. Vivino15, Zhao Yan16, Stephen Shiboski17, Troy Daniels18, John S. Greenspan6, Caroline H. Shiboski6 and Sjögren's Syndrome Collaborative Clinical Alliance (SICCA)19, 1Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 2Medicine, University of California San Francisco, San Francisco, CA, 3University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 4University of Washington, Biostatistics, Seattle, WA, 5Center for Inherited Disease Research, Baltimore, MD, 6Orofacial Sciences, University of California San Francisco, San Francisco, CA, 7Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 8Kings College London, London, United Kingdom, 9Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, 10University of Buenos Aires, Buenos Aires, Argentina, 11Oral and Maxillofacial Surgery, Rigshospitalet, Copenhagen, Denmark, 12Aravind Eye Hospital, Madurai, India, 13Kanazawa Medical University, Ishikawa, Japan, 14Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Ishikawa, Japan, 15Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, 16Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, 17Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, 18Orofacial Sciences, Box 0422, University of California San Francisco, San Francisco, CA, 19University of California San Francisco, San Francisco, CA

    Background/Purpose Our goal is to define the contribution of genetic factors to two hallmark manifestations of SS, keratoconjunctivitis sicca (KCS) and focal lymphocytic sialadenitis (FLS),…
  • Abstract Number: 233 • 2014 ACR/ARHP Annual Meeting

    Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study

    Mai Kawazoe, Kotaro Shikano, Kaichi Kaneko, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Sei Muraoka, Makoto Kaburaki, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan

    Background/Purpose:  Glucocorticoids are widely used to treat a variety of diseases, including systemic autoimmune diseases. Although glucocorticoids improve the outcome for patients with these diseases,…
  • Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Munther Khamashta1,2, Joan T. Merrill3, Victoria P. Werth4,5, Richard Furie6, Kenneth Kalunian7, Gabor G. Illei8, Jorn Drappa8, Liangwei Wang8 and Warren Greth8, 1Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, 2Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Philadelphia VA Medical Center, Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6North Shore-LIJ Health System, Lake Success, NY, 7UCSD School of Medicine, La Jolla, CA, 8MedImmune, LLC, Gaithersburg, MD

    Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
  • Abstract Number: 2956 • 2014 ACR/ARHP Annual Meeting

    Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina

    Paula S. Ramos1, Satria Sajuthi2, Jasmin Divers2, Yiqi Huang3, Uma Nayak4, Wei-Min Chen4, Kelly J. Hunt5, Diane L. Kamen6, Gary S. Gilkeson6, Jyotika K. Fernandes7, Ida J. Spruill7, W. Timothy Garvey8, Michèle M. Sale3 and Carl D. Langefeld2, 1Department of Medicine, Medical University of South Carolina, Charleston, SC, 2Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 3Department of Medicine and Center for Public Health Genomics, University of Virginia, Charlottesville, VA, 4Public Health Sciences, University of Virginia, Charlottesville, VA, 5Public Health Sciences, Medical University of South Carolina, Charleston, SC, 6Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 7Medical University of South Carolina, Charleston, SC, 8Department of Nutrition Sciences and Birmingham VA Medical Center, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose The reasons for the ethnic disparities in rheumatologic and autoimmune diseases (ADs) are largely unknown. We posit that population-specific selection influencing the allele frequencies…
  • Abstract Number: 2848 • 2014 ACR/ARHP Annual Meeting

    T-Cell Signaling Defects Can be Corrected By Manipulating ‘TCR Signal Fine-Tuning Molecules’ That Are Altered Due to Increased Ubiquitination in Systemic Autoimmune Disease

    Julia Pinkhasov1 and Ram Raj Singh1,2,3,4, 1Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, 2Interdepartmental Program in Molecular Toxicology, UCLA, Los Angeles, CA, 3Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, 4Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA

    Background/Purpose . T-cell selection in the thymus is primarily determined by the avidity of T cell receptor (TCR) for self-ligand-MHC. Since this process is dependent…
  • « Previous Page
  • 1
  • …
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology